Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Biomed Pharmacother. 2019 Sep;117:109199. doi: 10.1016/j.biopha.2019.109199. Epub 2019 Jul 5.
In recent years, immunotherapy has become an innovative technology for cancer therapy with the discovery of immunological checkpoints. It has shown great potential in a variety of advanced cancer treatments. Particularly, significant progress has been achieved in the understanding of programmed death-1/programmed death ligand-1 (PD-1/ PD-L1) pathway. Nivolumab, a human immunoglobulin (Ig)G4 PD-1 monoclonal antibody, was the first PD-1 inhibitor approved in the treatment of advanced non-small-cell lung cancer (NSCLC). Nivolumab has become a mainstay of first-line treatment of advanced/metastatic NSCLC without targetable genetic alterations. However, there are some questions in clinic that lacking of identifying biomarkers to predict the PD-1 immune checkpoint inhibition response. In this review, we summarize the results from recent clinical trials that have evaluated the nivolumab as first- or second- line treatment as monotherapy, in combination with chemotherapy and other immunotherapies. Also, we discuss the function of potential predicted biomarkers such as PD-L1 expression and tumor mutation burden in cancer treatment.
近年来，随着免疫检查点的发现，免疫疗法已成为癌症治疗的创新技术。它在多种晚期癌症治疗中显示出巨大的潜力。特别是，人们对程序性死亡受体 1/程序性死亡配体 1（PD-1/PD-L1）通路的理解取得了重大进展。纳武利尤单抗（nivolumab）是一种人免疫球蛋白（Ig）G4 PD-1 单克隆抗体，是首个获批用于治疗晚期非小细胞肺癌（NSCLC）的 PD-1 抑制剂。纳武利尤单抗已成为无靶向基因突变的晚期/转移性 NSCLC 一线治疗的基础药物。然而，临床上存在一些问题，缺乏识别生物标志物来预测 PD-1 免疫检查点抑制反应。在这篇综述中，我们总结了最近的临床试验结果，这些试验评估了纳武利尤单抗作为单药治疗、联合化疗和其他免疫疗法的一线或二线治疗的疗效。此外，我们还讨论了 PD-L1 表达和肿瘤突变负荷等潜在预测生物标志物在癌症治疗中的作用。
